The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 12:30 - 3:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 12:30 - 3:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 12:30 - 3:30 pm (CEST)
.If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Expression of IFN-γ by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA (5 ng/ml final concentration; Sigma Cat. #P-8139) and Ionomycin (500 ng/ml final concentration; Sigma Cat. #I0634) in the presence of GolgiPlug™ Protein Transport Inhibitor (1 µl/ml, Cat. No. 555029). The splenocytes were harvested and stained with 0.06 µg of FITC Rat Anti-Mouse CD4 (FITC-Rm4-5, Cat. No. 553047), fixed, permeabilized and subsequently stained with 0.12 µg of APC Rat IgG1 isotype control antibody (APC-R3-34, Cat. No. 554686, left panel) or with APC Rat Anti-Mouse IFN-γ (APC-XMG1.2, Cat. No. 554413, middle panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody (5.0 µg; Cat. No. 554409, right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control.
Expression of IFN-γ by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA (5 ng/ml final concentration; Sigma Cat. #P-8139) and Ionomycin (500 ng/ml final concentration; Sigma Cat. #I0634) in the presence of GolgiPlug™ Protein Transport Inhibitor (1 µl/ml, Cat. No. 555029). The splenocytes were harvested and stained with 0.06 µg of FITC Rat Anti-Mouse CD4 (FITC-Rm4-5, Cat. No. 553047), fixed, permeabilized and subsequently stained with 0.12 µg of APC Rat IgG1 isotype control antibody (APC-R3-34, Cat. No. 554686, left panel) or with APC Rat Anti-Mouse IFN-γ (APC-XMG1.2, Cat. No. 554413, middle panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody (5.0 µg; Cat. No. 554409, right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control.
Expression of IFN-γ by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA (5 ng/ml final concentration; Sigma Cat. #P-8139) and Ionomycin (500 ng/ml final concentration; Sigma Cat. #I0634) in the presence of GolgiPlug™ Protein Transport Inhibitor (1 µl/ml, Cat. No. 555029). The splenocytes were harvested and stained with 0.06 µg of FITC Rat Anti-Mouse CD4 (FITC-Rm4-5, Cat. No. 553047), fixed, permeabilized and subsequently stained with 0.12 µg of APC Rat IgG1 isotype control antibody (APC-R3-34, Cat. No. 554686, left panel) or with APC Rat Anti-Mouse IFN-γ (APC-XMG1.2, Cat. No. 554413, middle panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody (5.0 µg; Cat. No. 554409, right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control.
Expression of IFN-γ by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA (5 ng/ml final concentration; Sigma Cat. #P-8139) and Ionomycin (500 ng/ml final concentration; Sigma Cat. #I0634) in the presence of GolgiPlug™ Protein Transport Inhibitor (1 µl/ml, Cat. No. 555029). The splenocytes were harvested and stained with 0.06 µg of FITC Rat Anti-Mouse CD4 (FITC-Rm4-5, Cat. No. 553047), fixed, permeabilized and subsequently stained with 0.12 µg of APC Rat IgG1 isotype control antibody (APC-R3-34, Cat. No. 554686, left panel) or with APC Rat Anti-Mouse IFN-γ (APC-XMG1.2, Cat. No. 554413, middle panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody (5.0 µg; Cat. No. 554409, right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control.
Expression of IFN-γ by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA (5 ng/ml final concentration; Sigma Cat. #P-8139) and Ionomycin (500 ng/ml final concentration; Sigma Cat. #I0634) in the presence of GolgiPlug™ Protein Transport Inhibitor (1 µl/ml, Cat. No. 555029). The splenocytes were harvested and stained with 0.06 µg of FITC Rat Anti-Mouse CD4 (FITC-Rm4-5, Cat. No. 553047), fixed, permeabilized and subsequently stained with 0.12 µg of APC Rat IgG1 isotype control antibody (APC-R3-34, Cat. No. 554686, left panel) or with APC Rat Anti-Mouse IFN-γ (APC-XMG1.2, Cat. No. 554413, middle panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody (5.0 µg; Cat. No. 554409, right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control.
Expression of IFN-γ by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA (5 ng/ml final concentration; Sigma Cat. #P-8139) and Ionomycin (500 ng/ml final concentration; Sigma Cat. #I0634) in the presence of GolgiPlug™ Protein Transport Inhibitor (1 µl/ml, Cat. No. 555029). The splenocytes were harvested and stained with 0.06 µg of FITC Rat Anti-Mouse CD4 (FITC-Rm4-5, Cat. No. 553047), fixed, permeabilized and subsequently stained with 0.12 µg of APC Rat IgG1 isotype control antibody (APC-R3-34, Cat. No. 554686, left panel) or with APC Rat Anti-Mouse IFN-γ (APC-XMG1.2, Cat. No. 554413, middle panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody (5.0 µg; Cat. No. 554409, right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Recommended Assay Procedure:
Immunofluorescent Staining for Flow Cytometric Analysis: The APC-XMG1.2 antibody is useful for immunofluorescent staining and flow cytometric analysis to identify and enumerate IFN-γ producing cells within mixed cell populations. For optimal immunofluorescent staining for flow cytometric analysis, the anti-cytokine antibody should be titrated (≤ 0.5 µg mAb/million cells). For specific methodology, please visit the protocols section or chapter on intracellular staining in the Immune Function Handbook, both of which are posted on our web site, www.bdbiosciences.com.
A suitable rat IgG1 isotype control for assessing the level of background staining on paraformaldehyde-fixed/saponin-permeabilized mouse cells is APC-R3-34 (Cat. No. 554686); use at comparable concentrations to antibody of interest. A useful control for demonstrating specificity of staining is either of the following: (1) pre-block the APC-conjugated XMG1.2 antibody with ligand (e.g., recombinant mIFN-γ, Cat. No. 554587) prior to staining, or (2) pre-block the fixed/permeabilized cells with unlabeled XMG1.2 antibody (Cat. No. 554409) prior to staining.
The XMG1.2 monoclonal antibody specifically binds to mouse interferon-γ (IFN-γ) protein. IFN-γ is a pleiotropic cytokine, of approximately 15-17 kDa, involved in the regulation of inflammatory and immune responses. It plays an important role in activation, growth, and differentiation of T and B lymphocytes, macrophages, NK cells and other non-hematopoietic cell types. IFN-γ production is associated with the Th1 cell differentiation. The purified form of this antibody has been reported to be a neutralizing antibody.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.